0000899243-18-019968.txt : 20180717 0000899243-18-019968.hdr.sgml : 20180717 20180717204435 ACCESSION NUMBER: 0000899243-18-019968 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180717 FILED AS OF DATE: 20180717 DATE AS OF CHANGE: 20180717 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fust Matthew K CENTRAL INDEX KEY: 0001397266 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 18957549 MAIL ADDRESS: STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC. STREET 2: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6197 CORNERSTONE COURT, SUITE 111 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 6197 CORNERSTONE COURT, SUITE 111 CITY: SAN DIEGO STATE: CA ZIP: 92121 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-07-17 0 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001397266 Fust Matthew K C/O CRINETICS PHARMACEUTICALS, INC. 10222 BARNES CANYON ROAD, BLDG. #2 SAN DIEGO CA 92121 1 0 0 0 Common Stock 12536 D Stock Option (right to buy) 1.45 2027-11-05 Common Stock 5700 D Stock Option (right to buy) 1.91 2028-03-16 Common Stock 45592 D The option was initially granted with respect to 6,079 shares. 1/48th of the shares subject to the option vested on January 1, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. The option was partially exercised with respect to 379 shares on March 27, 2018, which shares are included in the total number of shares of common stock owned by the Reporting Person in Table I above. The option is exercisable as to vested and unvested shares. 1/3rd of the shares subject to the option vest on February 16, 2019, and 1/36th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. /s/ Marc Wilson, attorney-in-fact 2018-07-17